Uh oh... genentech (DNA) reports a great quarter, but the stock is slightly down in after-hours trading. Not sure what to make of this. Apparently revenue growth on some of the more established drugs was less than stellar. But it was made up for in spades by strong Lucentis sales. I'm not sure why the stock would be down on this news -- it seems as though Lucentis and Avastin provide DNA massive upside in the medium-term and justify the multiples.
It may be that the market has started pricing in these big upside surprises. If that's the case, Q3 is going to get ugly for the longs.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment